CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia

NCT07464951 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia (AML)

Interventions

BIOLOGICAL: Anti-CD123 LV redirected T cells (CART123)
DRUG: Ruxolitinib (JAKAVI®)

Sponsor

Stephan Grupp MD PhD

Collaborators

[object Object]